@文章{信息:doi/10.2196/32396，作者="Schnoor, Kyma和Versluis, Anke和Bakema, Robbert和van Luenen, Sanne和Kooij, Marcel J和van den Heuvel, J Maurik和Teichert, Martina和Honkoop, Persijn J和van Boven, Job F M和Chavannes, Niels H和Aardoom, Jiska J"，标题="基于药物的电子健康干预促进哮喘和COPD患者正确使用药物:非随机前后研究”，期刊=“J Med Internet Res”，年=“2022”，月=“6”，日=“8”，量=“24”，数=“6”，页数=“e32396”，关键词=“哮喘;慢性阻塞性肺病;药物治疗的依从性;急性加重;药房;背景:哮喘和慢性阻塞性肺病(COPD)影响着全球数百万人。虽然药物可以控制和改善疾病症状，但不正确使用药物是一个常见的问题。电子健康干预SARA(服务药剂师呼吸咨询)旨在通过提供信息和药剂师根据需要量身定制的后续支持，改善参与者正确使用吸入药物。目的:本研究的主要目的是探讨SARA对哮喘和COPD患者急性加重率的影响。 Secondary aims were to investigate its effects in terms of adherence to maintenance medication and antimycotic treatment. Methods: In this nonrandomized pre-post study, medication dispensing data from 382 Dutch community pharmacies were included. Exacerbation rates were assessed with dispensed short-course oral corticosteroids. Medication adherence between new and chronic users was assessed by calculating the proportion of days covered from dispensed inhalation maintenance medication. Antimycotic treatment was investigated from dispensed oral antimycotics in participants who were also dispensed inhaled corticosteroids (ICS). Outcomes were assessed 1 year before and 1 year after implementation of SARA and were compared between SARA participants and control participants. More specifically, for exacerbation rates and medication adherence, a difference score was calculated (ie, 1 year after SARA minus 1 year before SARA) and was subsequently compared between the study groups with independent-samples t tests. For antimycotics, the relative number of participants who were dispensed antimycotics was calculated and subsequently analyzed with a mixed-effects logistic regression. Results: The study population comprised 9452 participants, of whom 2400 (25.39{\%}) were SARA participants. The mean age of the population was 60.8 (15.0) years, and approximately two-thirds (n=5677, 60.06{\%}) were female. The results showed an increase in mean exacerbation rates over time for both study groups (SARA: 0.05; control: 0.15). However, this increase in exacerbation rates was significantly lower for SARA participants (t9450=3.10, 95{\%} CI 0.04-0.16; P=.002; Cohen d=0.06). Chronic users of inhalation medication in both study groups showed an increase in mean medication adherence over time (SARA: 6.73; control: 4.48); however, this increase was significantly higher for SARA participants (t5886=--2.74, 95{\%} CI --3.86 to --0.84; P=.01; Cohen d=--0.07). Among new users of inhalation medication, results showed no significant difference in medication adherence between SARA and control participants in the year after implementation of SARA (t1434=--1.85, 95{\%} CI --5.60 to 0.16; P=.06; Cohen d=--0.10). Among ICS users, no significant differences between the study groups were found over time in terms of the proportion of participants who were dispensed antimycotics (t5654=0.29, 95{\%} CI --0.40 to 0.54; P=.76; Cohen d=0). Conclusions: This study provides preliminary evidence that the SARA eHealth intervention might have the potential to decrease exacerbation rates and improve medication adherence among patients with asthma and COPD. ", issn="1438-8871", doi="10.2196/32396", url="//www.mybigtv.com/2022/6/e32396", url="https://doi.org/10.2196/32396", url="http://www.ncbi.nlm.nih.gov/pubmed/35675120" }